Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.

Cancer research - 15 Aug 1990

Klasa R J, Silver H K, Kong S

Abstract excerpt

In an effort to stimulate in vivo LAK cell activity at relatively nontoxic doses, 20 patients with advanced metastatic malignancy (13 renal cell carcinoma, 6 melanoma, 1 lymphoma) were treated with recombinant human interleukin-2 (IL-2) by continuous 5-day splenic artery perfusion using the femoral approach. Two treatment cycles were administered 3 weeks apart; IL-2 doses ranged from 1.5-4 x 10(4) Cetus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD
Share to Cytotoxicity, Immunologic
Share to HLA-DR Antigens

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Killer Cells, Natural

Share to Leukocyte Count

Share to Neoplasms

Share to Phenotype

Source

Identifiers

PMID: 2379154

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.PMID 2379154Read ↗

A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.Semantic proximity Read ↗

Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.Semantic proximity Read ↗

Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer.Semantic proximity Read ↗

Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.Semantic proximity Read ↗

Interleukin-2 activation of cytotoxic cells in postmastectomy seroma.Semantic proximity Read ↗

In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.Semantic proximity Read ↗

Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.Semantic proximity Read ↗

Improved lymphocyte cytotoxicity against murine renal cell carcinoma.Semantic proximity Read ↗

Regulatory effects of interleukin-4 on tumor-infiltrating lymphocytes derived from human renal cell carcinoma.Semantic proximity Read ↗

Liver sequestration of murine lymphokine activated killer (LAK) cells is mediated by carbohydrate-specific receptors.Semantic proximity Read ↗

Endolymphatic delivery of IL2 in patients with melanoma and lymphoma.Semantic proximity Read ↗

Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.